Technology of Beauty

"Conferences are where you go to see the interesting young companies coming into the space. And so we all have to attend. It's probably odd for a physician to see somebody from Wall Street attending a medical meeting, but we all do it." Imagine casually referencing how your company manages over $100 billion in assets. As the head of the biotechnology equity research team for William Blair & Company, Tim Lugo does just that in this interview with Dr. Grant Stevens. With all manner of aesthetic investments under his purview, Tim offers a uniquely embracive perspective on the aesthetic industry in this episode of The Technology of Beauty.

How does a brand with the eminence of Alastin manage the balancing act of pairing distinction and excellence with convenience and accessibility? After all, it's not exactly your average over-the-counter product line, so driving growth requires an innovative approach. In this episode of The Technology of Beauty, Global Head of Alastin Skincare Amber Edwards describes how Galderma's acquisition of Alastin has kicked expansion plans into overdrive. As she notes in this interview with Dr. Grant Stevens, Galderma's strategy is centered on taking Alastin global by maintaining credibility with physicians as an industry leader. "Providers have a challenge ahead of us to figure out how to deliver accessible convenient care," Amber says, "and we can't be status quo."

"I love the combination of energy with suture suspension, because I felt like that could take a patient who might need skin removal and change them into a patient who wouldn't need it, and we could address the underlying muscles without having to open the neck." A plastic surgeon practicing in Beverly Hills since 1998, Dr. Greg Mueller is first and foremost an aesthetic pioneer who counts the MyEllevate facial rejuvenation procedure and the Ovio360 Imaging System among his most significant inventions. In this interview with Dr. Grant Stevens, he reveals the history and the line of reasoning behind how MyEllevate came to be. And for a special treat for our surgical viewers and listeners, the two doctors proceed to dive into a spontaneous symposium on the procedure itself in the kind of exceptional technical detail that can only be found on The Technology of Beauty.

Plastic Surgeon. Professor. Scientist. The list of accolades is lengthy for Galderma's Chief Scientific Officer, Dr. Alan Widgerow - MBBCh(MD) MMed(MHS) FCS(Plast) FACS. And with Galderma's acquisition of Alastin, he continues to lead Alastin Innovations in his new expanded role as CSO for Galderma. Using in-house R&D and organic research to launch moonshots into uncharted realms of subcutaneous tissue at a cellular level, Professor Widgerow takes a disruptive yet wholly scientific approach to optimizing skin health and rejuvenation in his role at Galderma. In this episode of The Technology of Beauty, he gets technical in his analysis of the pros and cons of synthetic exosomes, autophagy, the role of waste management in dermal health, and much, much more. He also provides a look into a future featuring wearables that can tell you when you need to moisturize — and that's just a peek into what we have in store for you in this groundbreaking interview with Dr. Grant Stevens.

With an economic downturn looming on the horizon, patients still want to look their best — but they might not know how to pay for the procedures they desire. With his latest venture, Yes Doctor, Dr. Tim Sayed hopes to "optimize the market and lending rates for both patients and surgeons" by delivering fully qualified and financed patients directly to plastic surgeons. The rare plastic surgeon who is also versed in computer science and a licensed scrum master, Dr. Sayed sees other aesthetic financing solutions not as competitors, but potential partners in a shared platform for expanding lending opportunities while decreasing customer acquisition costs. Find out about all this and more in the latest episode of The Technology of Beauty.

It seems as though the hottest topic in aesthetics right now is exosomes. And if the research we're seeing tells us anything, herein lies the potential to remake the entire subject of healing, let alone revolutionizing aesthetics as we know it. Yes, it sounds almost exaggerated or absurd — but the science shows that the more we understand about exosomes, the more likely it is that we can leverage the body's own regenerative potential to encourage targeted healing. Rion's Commercial Lead Jodi Brichan joins Dr. Grant Stevens for a fascinating interview, wherein she does a far better job than we can of exploring a technology that seeks to restore beauty by healing what needs to be healed on an individualized basis. The future is approaching at breakneck speed, so tune in for this next episode of The Technology of Beauty to find out how these abstract theories about exosomes are about to hit the market in the form of versatile new aesthetic products with a variety of innovative applications.

On this week's episode we hear from a man with an innovative vision for the future of aesthetics real estate — Cloud Medspas. Vansanity Founder Ignacio Fanlo sits down in the studio to discuss how the startup's Silicon-Valley-inspired business model is empowering independent providers through on-demand access to treatment space, capital equipment, and product, as well a host of ongoing business support services.  While some aesthetic professionals may not find the cutting edge of business innovation as compelling as the cutting edge of aesthetics techniques, this episode may surprise you. After all, this is The Technology of Beauty, where we cover all facets of aesthetic innovation, including developments in aesthetic practice management. Tune in to find out how Vansanity is working to create new opportunities for aesthetic entrepreneurs on the latest episode of The Technology of Beauty.

In this episode of The Technology of Beauty, Dr. Grant Stevens interviews CEO Brian Phillips & CCO Sean Shapiro of MedShift. By offering bundled subscription services for state-of-art equipment and technology, MedShift provides mutual benefit for practices and manufacturers. Doctors can choose from a menu of industry-leading aesthetic devices and begin delivering services to patients without footing the bill for upfront costs. For the manufacturers, MedShift offers fully integrated software solutions to help improve device management by identifying common obstacles to implementation. Find out how MedShift's aesthetic focus helps them identify and solve unique issues with next-gen tech in this latest episode of The Technology of Beauty.

Galderma recently made national headlines with a new neurotoxin that promises rapid onset and long duration up to 6 months — and while that may sound too good to be true, the data comes directly from two phase III clinical studies. If that were the only news Galderma CEO Flemming Ørnskov had for us, it would be worthy of an episode in itself. But in this interview with Dr. Grant Stevens, he announces that Galderma will be launching a total of 22 new products this year alone! Tune in to hear all this and more on the latest episode of The Technology of Beauty.

It’s one thing to say you want to do a better job in aesthetic medicine, to enhance your offerings, and “be part of something bigger.” It’s another thing entirely to actually achieve it. Drawing on experience gained as an executive at Lumenis, Biolase, Allergan and Medicis, Athenix CEO James Haefner set out to find a way to achieve consistent, reproducible results while maximizing the value of a practice. And in creating the Athenix Body Sculpting Institute, James built a model for providing plastic surgeons with key back-end support functions including marketing, accounting, HR, operations, regulatory and licensing — allowing doctors to focus their attention on patient satisfaction. In this episode of the Technology of Beauty, discover how James ultimately drafted a blueprint for group practice success that consistently ranks among the top plastic surgery practices in the U.S.